{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:14:16Z","timestamp":1758053656761,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R24HD047879"],"award-info":[{"award-number":["R24HD047879"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","award":["M-360"],"award-info":[{"award-number":["M-360"]}],"id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011948","name":"Abbott Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.contraception.2012.06.010","type":"journal-article","created":{"date-parts":[[2012,8,11]],"date-time":"2012-08-11T00:16:26Z","timestamp":1344644186000},"page":"327-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Communicating risk: does scientific debate compromise safety?"],"prefix":"10.1016","volume":"86","author":[{"given":"Jeffrey T.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Trussell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2012.06.010_bb0005","doi-asserted-by":"crossref","first-page":"e2990","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001\u201310","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2012.06.010_bb0010","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2012.06.010_bb0015","series-title":"Contraceptive technology","article-title":"Choosing a contraceptive: efficacy, safety, and personal considerations","author":"Trussell","year":"2011"},{"key":"10.1016\/j.contraception.2012.06.010_bb0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.semperi.2011.09.002","article-title":"Overview of maternal mortality in the United States","volume":"36","author":"Callaghan","year":"2012","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.contraception.2012.06.010_bb0025","first-page":"161","article-title":"Motor vehicle-related death rates \u2014 United States, 1999\u20132005","volume":"58","author":"MMWR","year":"2009","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.contraception.2012.06.010_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.contraception.2010.04.006","article-title":"Factors affecting mortality in a large cohort study with special reference to oral contraceptive use","volume":"82","author":"Vessey","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2012.06.010_bb0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jfprhc-2011-14524","article-title":"Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel","volume":"37","author":"Heinemann","year":"2011","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2012.06.010_bb0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1783\/147118910790291037","article-title":"Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies","volume":"36","author":"Shapiro","year":"2010","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2012.06.010_bb0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2012.06.010_bb0050","doi-asserted-by":"crossref","unstructured":"British Medical Journal rapid responses. Available at: http:\/\/www.bmj.com\/content\/344\/bmj.e2990?tab=responses. (date accessed 10 June 2012).","DOI":"10.1136\/bmj.e2990"},{"key":"10.1016\/j.contraception.2012.06.010_bb0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2288-9-77","article-title":"International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study)","volume":"9","author":"Dinger","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.contraception.2012.06.010_bb0060","unstructured":"Bayer Healthcare Pharmaceuticals drospirenone-containing combination oral contraceptives briefing document. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM282464.pdf. (date accessed: 10 June 2012)."},{"key":"10.1016\/j.contraception.2012.06.010_bb0065","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.AOG.0000279448.62221.a8","article-title":"Risk of thromboembolism in women taking ethinylestradiol\/drospirenone and other oral contraceptives","volume":"110","author":"Seeger","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2012.06.010_bb0070","unstructured":"Dinger JC, Pineda AA. Risk of VTE in users of an etonogestrel-containing vaginal ring and combined oral contraceptives (abstract presented at the 61st Annual ACOG meeting). Available at: http:\/\/classic.acog.org\/acm\/pdf\/oralMon748.pdf. (date accessed 10 June 2012)."},{"key":"10.1016\/j.contraception.2012.06.010_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.contraception.2010.02.014","article-title":"Adaptation of the World Health Organization's medical eligibility criteria for contraceptive use for use in the United States","volume":"82","author":"Curtis","year":"2010","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782412006427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782412006427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:10:01Z","timestamp":1757880601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782412006427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0010782412006427"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2012.06.010","relation":{},"ISSN":["0010-7824"],"issn-type":[{"type":"print","value":"0010-7824"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Communicating risk: does scientific debate compromise safety?","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2012.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}